Futibatinib

Brand names: Lytgobi · Active ingredient: Futibatinib

In short: LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements . This indication is approved under accelerated ap

Forms & strengthsTablets: 4 mg, round, white, film-coated tablets debossed with “4MG” on one side, and “FBN” on the other side.
LabelTaiho Pharmaceutical Co., Ltd.
Label updatedNov 09, 2026

What is Futibatinib used for?

LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements .

This indication is approved under accelerated approval based on overall response rate and duration of response . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Futibatinib dosage

Select patients for the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with LYTGOBI based on the presence of an FGFR2 gene fusion or rearrangement .

An FDA-approved test for detection of FGFR2 gene fusions or other rearrangements in patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma for selecting patients for treatment with LYTGOBI is not available.

The recommended dosage of LYTGOBI is 20 mg taken orally once daily until disease progression or unacceptable toxicity occurs.

Take LYTGOBI with or without food at approximately the same time each day .

Swallow tablets whole. Do not crush, chew, split, or dissolve tablets.

If the patient misses a dose of LYTGOBI for more than 12 hours or if vomiting occurs after taking the dose, skip the dose and resume dosing with the next scheduled dose.

The recommended dose reductions for adverse reactions are provided in Table 1.

Dose Reduction | Recommended Dosage

First dose reduction | 16 mg orally once daily

Second dose reductionPermanently discontinue LYTGOBI if unable to tolerate 12 mg orally once daily. | 12 mg orally once daily

Recommended dosage modifications for adverse reactions are provided in Table 2.

Adverse Reaction | Severity | LYTGOBI Dosage Modifications

a Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 4.03).

Retinal Pigment Epithelial Detachment (RPED)

| Not applicable | Continue LYTGOBI at the current dose and continue periodic ophthalmic evaluation:

If resolving within 14 days, continue LYTGOBI at the current dose.

If not resolving within 14 days, withhold LYTGOBI until resolving; then resume LYTGOBI at previous or a lower dose.

Hyperphosphatemia

| Serum phosphate ≥5.5 - ≤7 mg/dL | Continue LYTGOBI at the current dose and initiate phosphate lowering therapy. Monitor serum phosphate weekly.

Serum phosphate >7 - ≤10 mg/dL | Initiate or adjust phosphate lowering therapy. Monitor serum phosphate weekly and

Dose reduce LYTGOBI to next lower dose

-If the serum phosphate resolves to ≤7 mg/dL within 2 weeks after dose reduction, continue at this reduced dose.

-If serum phosphate is not ≤7 mg/dL within 2 weeks, further reduce LYTGOBI to the next lower dose.

-If serum phosphate is not ≤7 mg/dL within 2 weeks after the second dose reduction, withhold LYTGOBI until serum phosphate is ≤7 mg/dL and resume at the dose prior to suspending.

Serum phosphate >10 mg/dL | Initiate or adjust phosphate lowering therapy and monitor serum phosphate weekly and

Withhold LYTGOBI until phosphate is ≤7 mg/dL and resume LYTGOBI at the next lower dose.

-Permanently discontinue LYTGOBI if serum phosphate is not ≤7 mg/dL within 2 weeks following 2 dose interruptions and reductions. …

How to take Futibatinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Ocular Toxicity

Advise patients that LYTGOBI may cause ocular toxicity including RPED and to immediately inform their healthcare provider if they experience any visual changes . Advise patients to use artificial tears, or hydrating or lubricating eye gels to prevent or treat dry eyes .

Hyperphosphatemia and Soft Tissue Mineralization

Inform patients that LYTGOBI may cause hyperphosphatemia and soft tissue mineralization and to immediately inform their healthcare provider of any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth .

Nail Disorders

Advise patients that LYTGOBI may cause nail disorders .

Embryo-Fetal Toxicity

Advise females to inform their healthcare provider if they are pregnant or become pregnant. Inform female patients of the risk to a fetus and potential loss of pregnancy .

Advise females of reproductive potential to use effective contraception while on LYTGOBI and for 1 week after the last dose . …

Warnings & precautions

Do not take this medicine if: None.

Retinal Pigment Epithelial Detachment (RPED)

LYTGOBI can cause RPED, which may cause symptoms such as blurred vision.

Among 318 patients who received LYTGOBI across clinical trials where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 9% of patients. The median time to first onset of RPED was 40 days. RPED led to dose interruption of LYTGOBI in 1.3% of patients, dose reduction in 1.6% of patients, and permanent discontinuation in 0.3% of patients.

Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 6 months, and every 3 months thereafter. For onset of visual symptoms, refer patients for ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of LYTGOBI.

Withhold or reduce the dose of LYTGOBI as recommended .

Dry Eye/Corneal Keratitis

Among 318 patients who received LYTGOBI across clinical trials , dry eye occurred in 15% of patients. Treat patients with ocular demulcents as needed.

LYTGOBI can cause hyperphosphatemia leading to soft tissue mineralization, calcinosis, nonuremic calciphylaxis, and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of LYTGOBI . Among 318 patients who received LYTGOBI across clinical trials , hyperphosphatemia was reported in 88% of patients based on laboratory values above the upper limit of normal. The median time to onset of hyperphosphatemia was 5 days (range 3-117). Phosphate binders were received by 77% of patients who received LYTGOBI.

Monitor for hyperphosphatemia throughout treatment. Initiate a low phosphate diet and phosphate lowering therapy when serum phosphate level is ≥5.5 mg/dL. …

Futibatinib side effects

The following adverse reactions are discussed elsewhere in the labeling:

Ocular Toxicity

Hyperphosphatemia and Soft Tissue Mineralization

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to LYTGOBI as a single agent at 20 mg orally once daily in 318 patients including 145 patients with cholangiocarcinoma and 173 patients with other advanced solid tumors. Among 318 patients who received LYTGOBI, 37% were exposed for 6 months or longer and 13% were exposed for greater than 12 months.

Previously Treated, Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

The safety of LYTGOBI was evaluated in Study TAS-120-101, which included 103 patients with previously treated, unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or other gene rearrangements . Patients were treated with LYTGOBI 20 mg orally once daily until disease progression or unacceptable toxicity. The median duration of treatment was 9 months (range: 0.5 - 25 months).

Serious adverse reactions occurred in 39% of patients receiving LYTGOBI. …

Drug interactions

Strong CYP3A Inhibitors

Avoid concomitant use of strong CYP3A inhibitors with LYTGOBI.

Futibatinib is a CYP3A substrate . Concomitant use of a strong CYP3A inhibitor increases futibatinib exposure , which may increase the risk of adverse reactions.

Strong CYP3A Inducers

Avoid concomitant use of strong CYP3A inducers with LYTGOBI.

Futibatinib is a CYP3A substrate . Concomitant use of a strong CYP3A inducer decreases futibatinib exposure , which may reduce the effectiveness of LYTGOBI.

About this medicine

Futibatinib is a kinase inhibitor with the chemical name 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]- 1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one. Futibatinib has a molecular formula of C22H22N6O3 and molecular mass of 418.45 g/mole. Futibatinib has the following chemical structure:

Futibatinib is a white crystalline powder. The solubility of futibatinib is pH dependent with decreasing solubility with increasing pH, being practically insoluble at pH 3 or higher. Futibatinib is insoluble in water and poorly soluble in common solvents. LYTGOBI is supplied as 4 mg film-coated tablets for oral administration. Each tablet contains inactive ingredients of corn starch, crospovidone, hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, and sodium lauryl sulfate. The film coating material contains hypromellose, magnesium stearate, polyethylene glycol, and titanium dioxide.

How it works: Futibatinib is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4 with IC50 values of less than 4 nM. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 0b1332a1-0581-4707-9bf6-1eccfa39bef4. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate